ArticleFrontiers in drug safety and regulation2025
Implementing tokenization in clinical research to expand real-world insights.
Article in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings.Frontiers in drug safety and regulation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in leveraging real-world data (RWD) to support clinical research is increasing, including studies to further characterize safety and effectiveness of new treatments. Such studies often require a combination of primary, study-specific data, with secondary, existing RWD. So-called enriched studies are becoming more common but require tailored methodologies that facilitate linkage across data sources. Tokenization has emerged as a key tool in the United States (US) to enable the linkage of secondary data with primary data, although key considerations to operationalize tokenization are often overlooked during study set-up. This article aims to explore key aspects for implementing tokenization in the US and to define relevant terminology. Appropriate study designs and RWD sources to leverage this tool are also discussed and advantages and considerations for study stakeholders to enhance possibilities to generate real-world evidence are highlighted. The article concludes with a description of case studies where tokenization is a suitable fit to fulfill study goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.